Arca
Skip to content

Chronic myelogenous leukemia (cml)

Drug research and approvals for chronic myelogenous leukemia (cml): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 95 studies of chronic myelogenous leukemia (cml) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 20 approved and 16 open orphan designations naming it, and the EU has 10 authorised medicines for it.

  • Recruiting worldwide: 95
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 20
  • EU medicines: 10

Recruiting Now

Newest start dates first, of 95 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Feb 27, 2026A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously…ASCIMINIB (ABL001)Novartis Pharmaceuticals CorporationOngoing
Feb 12, 2026Asciminib, with or without dasatinib combination, as a 2nd-line therapy to advance the treatment for chronic myelogenous leukemia in chronic phase (asc2advance)ASCIMINIBUNIVERSITY HEALTH NETWORKOngoing
May 10, 2022A phase 3, multicenter, randomized, open-label, trial evaluating the efficacy and safety of asciminib (abl001) used in consolidation with imatinib vs. imatinib…ASCIMINIB (ABL001)JEWISH GENERAL HOSPITALClosed
Oct 27, 2021A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with chronic myelogenous leukemia in chronic phase (cml-cp)…ASCIMINIB (ABL001)Novartis Pharmaceuticals CorporationClosed
Sep 27, 2021A phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected tki in patients with newly diagnosed philadelphia…ASCIMINIB (ABL001)Novartis Pharmaceuticals CorporationOngoing
Sep 14, 2021An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a novartis sponsored asciminib study and are…ASCIMINIB (ABL001) / IMATINIB (STI571)Novartis Pharmaceuticals CorporationOngoing
Aug 27, 2021Phase 3 randomized, controlled study of blinatumomab alternating with low-intensity chemotherapy versus standard of care for older adults with newly diagnosed…BLINCYTOAmgenOngoing
Sep 14, 2018A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with…ASCIMINIB (ABL001)/ IMATINIB/ NILOTINIBNovartis Pharmaceuticals CorporationClosed
Jun 15, 2017A phase 3, multi-center,open-label, randomized study of oral abl001 versus bosutinib in patients with chronic myelogenous leukemia in chronic pahse (cml-cp),…ASCIMINIB (ABL-001)/ BOSUTINIBNovartis Pharmaceuticals CorporationClosed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 36
May 29, 2026Cavhanzatreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and…Cycle Pharmaceuticals LtdApproved
Aug 1, 2025Phyragotreatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in…Handa Therapeutics, LLCApproved
Nov 7, 2024Danzitentreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and…Azurity Pharmaceuticals, Inc.Approved
Oct 29, 2024Scemblixtreatment of adult patients with previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase…Novartis Pharmaceuticals CorporationApproved
Oct 29, 2024Scemblixtreatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)Novartis Pharmaceuticals CorporationApproved
Dec 5, 2023Phyragotreatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;…Handa Therapeutics, LLCApproved
Sep 26, 2023Bosuliftreatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome positive chronic myelogenous…PF PRISM C.V.Approved
Oct 29, 2021ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously…Novartis Pharmaceuticals CorporationApproved
Oct 29, 2021ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I…Novartis Pharmaceuticals CorporationApproved
Sep 23, 2021TasignaTreatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome…Novartis Pharmaceuticals CorporationApproved
Mar 22, 2018TasignaTASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed…Novartis Pharmaceuticals CorporationApproved
Dec 19, 2017BosulifBOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic…PF PRISM C.V.Approved
Nov 9, 2017SprycelTreatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phaseBristol-Myers Squibb CompanyApproved
Dec 14, 2012IclusigTreatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or…Takeda Pharmaceuticals U.S.A., Inc.Approved
Oct 26, 2012SynriboTreatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or…IVAX International GmbHApproved

Medicines Authorised in the EU

Newest first
Aug 22, 2024Nilotinib Accordnilotinib · genericAccord Healthcare S.L.U.EMA ↗
Jul 26, 2024Dasatinib Accord Healthcaredasatinib · genericAccord Healthcare S.L.U.EMA ↗
Aug 25, 2022Scemblixasciminib · orphanNovartis Europharm LimitedEMA ↗
Jul 1, 2013IclusigponatinibIncyte Biosciences Distribution B.V.EMA ↗
Jun 30, 2013Imatinib Accordimatinib · genericAccord Healthcare S.L.U.EMA ↗
Mar 27, 2013BosulifbosutinibPfizer Europe MA EEIGEMA ↗
Jan 7, 2013Imatinib Tevaimatinib · genericTeva B.V.EMA ↗
Nov 19, 2007TasignanilotinibNovartis Europharm LimitedEMA ↗
Nov 20, 2006Spryceldasatinib (anhydrous)Bristol-Myers Squibb Pharma EEIGEMA ↗
Nov 7, 2001GlivecimatinibNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.